您的位置: 首页 > 农业专利 > 详情页

Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
专利权人:
TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz Gemeinnützige GmbH;Ganymed Pharmaceuticals GmbH
发明人:
Sahin, Ugur,Türeci, Özlem,Mitnacht-Kraus, Rita,Jacobs, Stefan Denis,Utsch, Magdalena Jadwiga,Heinz, Cornelia Adriana Maria,Stadler, Christiane Regina
申请号:
NZ72534713
公开号:
NZ725347A
申请日:
2013.05.21
申请国别(地区):
NZ
年份:
2018
代理人:
摘要:
The present invention provides a combination therapy combination therapy comprising an antibody having the ability of binding to CLDN18.2 with an agent stabilizing or increasing expression of CLDN18.2 for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/
相关发明人
相关专利

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充